Skip to main content
. 2019 Aug 6;18(4):3887–3895. doi: 10.3892/ol.2019.10715

Figure 1.

Figure 1.

mPFS of patients with the exon 19-del or 21-L858R mutation administered with different treatment types. (A) The mPFS times for patients harboring the 19-del and 21-L858R mutation were 11.3 and 8.8 months (P=0.017), respectively, following use of first-line TKIs. (B) The mPFS times for patients harboring the 19-del and 21-L858R mutation were 8.0 and 3.5 months (P=0.105), respectively, following first-line chemotherapy. (C) The mPFS times for patients harboring the 19-del and 21-L858R mutation were 11.0 and 13.6 months (P=0.090), respectively, following use of second-line TKIs. mPFS, median progression-free survival; TKIs, tyrosine kinase inhibitors.